Plecanatide (Trulance)

1. Overview

Plecanatide is a synthetic 16-amino-acid peptide that functions as a guanylate cyclase-C (GC-C) agonist, approved by the FDA for the treatment of chronic idiopathic constipation (CIC) in January 2017 and irritable bowel syndrome with constipation (IBS-C) in January 2018 [1][3][9]. Marketed under the brand name Trulance, it was developed by Synergy Pharmaceuticals and is currently commercialized by Salix Pharmaceuticals, a subsidiary of Bausch Health Companies.

Plecanatide was designed as a structural analog of human uroguanylin, one of two endogenous peptide ligands for the GC-C receptor (the other being guanylin) [7][10]. Its amino acid sequence differs from native uroguanylin by a single substitution: leucine at position 3 is replaced by aspartic acid, which enhances receptor binding affinity while preserving the pH-dependent activation characteristics of the parent peptide [7]. Like uroguanylin, plecanatide possesses two intramolecular disulfide bonds (Cys4-Cys12 and Cys7-Cys15), distinguishing it from linaclotide, which contains three disulfide bonds and is structurally more closely related to the bacterial heat-stable enterotoxin STa [7][12].

The clinical development of plecanatide was driven by the hypothesis that a uroguanylin-based GC-C agonist with pH-dependent activity -- preferentially activating GC-C in the mildly acidic environment (pH 5.0-6.0) of the proximal small intestine rather than uniformly throughout the GI tract -- would produce a more physiological pattern of intestinal secretion with improved tolerability compared to pH-independent agonists like linaclotide [7]. This design rationale has clinical significance: the lower diarrhea rate observed with plecanatide compared to linaclotide may reflect this mechanistic distinction.

Molecular Weight

1681.9 g/mol

Molecular Formula

C65H104N16O26S4

Structure

16-amino-acid peptide with 2 disulfide bonds (Cys4-Cys12, Cys7-Cys15); analog of uroguanylin

Half-life

Not measurable systemically (local GI action)

Bioavailability

Negligible (less than 0.1% oral bioavailability)

Routes

Oral (tablet, with or without food)

FDA Status

Approved (CIC January 2017; IBS-C January 2018)

Dose

3 mg once daily (both CIC and IBS-C)

Manufacturer

Salix Pharmaceuticals (Bausch Health Companies)

2. Mechanism of Action

2.1 GC-C Activation and cGMP Signaling

Plecanatide binds to the extracellular domain of guanylate cyclase-C on the apical surface of intestinal epithelial cells, stimulating conversion of GTP to cyclic GMP (cGMP) [7][12]. Elevated intracellular cGMP activates cGMP-dependent protein kinase II (PKG-II), which phosphorylates and activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel on the apical membrane [12]. This drives chloride and bicarbonate secretion into the intestinal lumen, followed by paracellular sodium and water movement, increasing luminal fluid volume, softening stool, and accelerating transit [7][12].

2.2 pH-Dependent Activation

A distinguishing pharmacological feature of plecanatide is its pH-dependent GC-C activation profile [7]. In vitro studies by Shailubhai et al. (2015) demonstrated that plecanatide achieves maximal GC-C activation at pH 5.0, with progressively lower activity at higher pH values, closely mimicking the pH-activity relationship of endogenous uroguanylin [7]. This contrasts with linaclotide, which activates GC-C independently of ambient pH due to its three-disulfide-bond structure derived from the bacterial STa scaffold [12][17].

The physiological rationale is that uroguanylin normally functions as a pH sensor in the proximal small intestine, where luminal pH is 5.0-6.5 following gastric acid delivery. By replicating this pH-dependent activation, plecanatide was hypothesized to produce secretory stimulation predominantly in the proximal gut, where it could be most effective for symptom relief while minimizing excessive colonic secretion that contributes to diarrhea [7].

2.3 Visceral Pain Modulation

Like linaclotide, plecanatide generates extracellular cGMP that is exported across the basolateral membrane of enterocytes, where it acts as a paracrine mediator to inhibit colonic nociceptors and reduce visceral pain signaling [12][13]. Clinical trials confirmed that plecanatide significantly reduces abdominal pain in IBS-C patients, with improvement beginning as early as week 1 [3][4].

3. Pharmacokinetics

3.1 Oral Absorption and Local Action

Plecanatide is designed to act exclusively within the gastrointestinal lumen, representing a fundamentally different pharmacokinetic paradigm from most pharmaceutical agents [5][9]:

Negligible systemic absorption. Following oral administration of 3 mg tablets, plasma concentrations of both plecanatide and its primary active metabolite (des-Tyr16-plecanatide, formed by C-terminal tyrosine removal by intestinal carboxypeptidases) are consistently below the lower limit of quantitation (approximately 10 pg/mL) in formal pharmacokinetic studies [5][9]. The oral bioavailability is estimated at less than 0.1%, making systemic PK parameters (AUC, Cmax, Tmax, half-life, volume of distribution, clearance) not measurable or applicable [9].

Mechanism of non-absorption. Several factors ensure that plecanatide remains in the GI lumen:

• The two disulfide bonds maintain a compact tertiary structure resistant to passive paracellular absorption
• The molecular weight (1682 Da) and hydrophilic character prevent significant transcellular permeation
• Active degradation by luminal proteases and disulfide reductases progressively inactivates the peptide as it transits distally through the intestine
• The GC-C receptor is expressed exclusively on the apical (luminal) surface of intestinal epithelial cells, so only luminal drug is pharmacologically active [9][12]

3.2 Intraluminal Degradation

Within the GI tract, plecanatide undergoes stepwise degradation [9]:

1. Carboxypeptidase cleavage: Removal of the C-terminal tyrosine (Tyr16) by intestinal carboxypeptidases generates des-Tyr16-plecanatide, which retains full GC-C agonist activity
2. Disulfide bond reduction: Intestinal glutathione and thioredoxin systems reduce the two disulfide bonds, unfolding the peptide and abolishing receptor binding
3. Protease digestion: The linearized peptide is further degraded by pancreatic and brush-border proteases (trypsin, chymotrypsin, aminopeptidases) into constituent amino acids
4. Complete degradation: By the time intestinal contents reach the distal colon, the majority of plecanatide has been degraded to pharmacologically inactive fragments

This progressive degradation gradient -- with highest active drug concentration in the proximal small intestine (where pH is optimal for activation) and diminishing activity distally -- is proposed as the mechanistic basis for the lower diarrhea rate compared to linaclotide [7][9].

3.3 pH-Dependent Activation Kinetics

The pharmacodynamic activation of plecanatide is governed by luminal pH, creating a unique "activation pharmacokinetics" profile distinct from conventional drug absorption [7]:

| GI Segment | Luminal pH | Relative GC-C Activation | Pharmacological Consequence | |------------|-----------|--------------------------|---------------------------| | Duodenum | 5.0-6.0 | Maximal (100%) | Peak secretory stimulation | | Jejunum | 6.0-7.0 | Moderate (50-70%) | Continued fluid secretion | | Ileum | 7.0-7.5 | Low (20-40%) | Diminishing effect | | Colon | 7.0-8.0 | Minimal (10-20%) | Minimal excess secretion |

This pH-dependent activation gradient is the proposed mechanistic explanation for plecanatide's lower diarrhea rate compared to linaclotide (which activates GC-C equivalently at all pH values and therefore produces more colonic secretion) [7][12].

3.4 Food Effect

Unlike linaclotide, which demonstrates a significant food effect (higher diarrhea rates when taken with food, leading to the recommendation to take it on an empty stomach), plecanatide shows no clinically meaningful food effect on efficacy or tolerability [9]. This allows flexible dosing with or without food, representing a practical convenience advantage for patients.

3.5 Drug Interactions

No drug-drug interactions have been identified or are expected because plecanatide is not absorbed systemically, does not interact with CYP450 enzymes, and does not bind to plasma proteins [9]. No dose adjustments are required for hepatic or renal impairment, as these organs are not involved in the drug's action or elimination [9].

4. Dose-Response Relationships

4.1 CIC Dose-Response

The Phase III CIC program evaluated both 3 mg and 6 mg doses, establishing a clear dose-response and dose-selection rationale [1][2]:

| Endpoint | Placebo | Plecanatide 3 mg | Plecanatide 6 mg | |----------|---------|------------------|------------------| | Trial 1 (Miner) | | | | | CSBM overall responder | 10.2% | 21.0% (p value below 0.001) | 19.5% (p value below 0.001) | | CSBM frequency responder | 13.1% | 23.6% | 22.0% | | Diarrhea rate | 1.3% | 5.9% | 5.4% | | Trial 2 (DeMicco) | | | | | CSBM overall responder | 12.8% | 20.1% (p value below 0.01) | 17.8% (p value below 0.05) | | CSBM frequency responder | 16.0% | 24.6% | 22.2% | | Diarrhea rate | 1.4% | 4.3% | 6.0% |

Key dose-response observations:

• The 3 mg dose produced numerically superior or equivalent efficacy compared to 6 mg across all endpoints
• The 6 mg dose showed a trend toward higher diarrhea rates without additional efficacy benefit
• The inverted dose-response (3 mg more effective than 6 mg) was not statistically significant but was consistent across both trials
• This pattern is pharmacologically plausible: optimal GC-C activation may require moderate rather than maximal receptor stimulation, and excess stimulation may trigger counter-regulatory mechanisms

The 3 mg dose was selected for commercialization as the optimal balance of efficacy and tolerability [1][2][9].

4.2 IBS-C Dose-Response

Only the 3 mg dose was evaluated in Phase III IBS-C trials (based on CIC dose-selection results), so direct dose-response data within IBS-C are limited to Phase II exploration [3][4]:

Phase III IBS-C Results at 3 mg: | Endpoint | Trial 1 (Brenner) | Trial 2 (Miner) | |----------|-------------------|-----------------| | FDA composite responder | 30.2% vs 17.8% placebo | 24.3% vs 14.2% placebo | | Abdominal pain responder | 22.0% vs 14.9% placebo | 21.4% vs 13.6% placebo | | CSBM responder | 24.4% vs 15.1% placebo | 22.1% vs 13.5% placebo | | Time to onset of pain relief | Week 1 | Week 1 |

4.3 Temporal Response Pattern

The onset and durability of plecanatide's effects follow a characteristic pattern [1][3][4]:

• Week 1: Statistically significant improvement in stool frequency and consistency; initial improvement in abdominal pain (IBS-C)
• Week 2-4: Progressive improvement across all endpoints; maximum separation from placebo
• Week 4-12: Sustained efficacy with no evidence of tachyphylaxis
• Post-discontinuation: Effects are not sustained after stopping therapy, consistent with the lack of disease modification (symptomatic treatment only)

4.4 Response Predictors

Across Phase III trials, the following baseline characteristics were associated with greater likelihood of response to plecanatide [1][3][4]:

• Lower baseline CSBM frequency (more severe constipation at baseline)
• Higher baseline abdominal pain scores (more room for improvement)
• Female sex (modest trend)
• No significant effect of age, race, or BMI on response rates

5. Clinical Evidence

5.1 CIC Phase III Trials

Trial 1 (Miner et al., 2017): A 12-week randomized, double-blind, placebo-controlled trial enrolled 1,394 adults with CIC (Rome III criteria) randomized to plecanatide 3 mg, 6 mg, or placebo once daily [1]. The primary endpoint was the CSBM overall responder rate (three or more CSBMs per week with an increase of one or more from baseline for at least 9 of 12 weeks). Plecanatide 3 mg achieved a 21.0% responder rate versus 10.2% placebo (p value below 0.001). Plecanatide 6 mg achieved 19.5% vs placebo. Both doses significantly improved secondary endpoints including CSBM frequency, stool consistency, and straining [1].

Trial 2 (DeMicco et al., 2017): A parallel 12-week Phase III RCT in 1,377 adults with CIC [2]. CSBM overall responder rates were 20.1% (3 mg) and 17.8% (6 mg) versus 12.8% placebo (p value below 0.01 for 3 mg). The 3 mg dose was selected for commercialization because it demonstrated equivalent or superior efficacy to 6 mg with better tolerability [2].

5.2 IBS-C Phase III Trials

Trial 1 (Brenner et al., 2018): This pivotal 12-week RCT enrolled 2,189 adults with IBS-C (Rome III criteria) randomized to plecanatide 3 mg or placebo [3]. The FDA composite primary endpoint required simultaneous improvement in abdominal pain (30% or more reduction from baseline) and CSBM frequency (increase of one or more from baseline) for at least 6 of 12 weeks. The composite responder rate was 30.2% for plecanatide versus 17.8% for placebo (p value below 0.001) [3].

Trial 2 (Miner et al., 2019): A second IBS-C Phase III trial in 2,200 adults confirmed efficacy with a combined responder rate of 24.3% versus 14.2% placebo (p value below 0.001) [4]. Abdominal pain improvement was significant by week 1 and sustained throughout the treatment period [4].

6. Comparative Effectiveness

6.1 Plecanatide vs Linaclotide: The Central Comparison

Plecanatide and linaclotide are the only two approved GC-C agonists and represent the primary comparator pair in this therapeutic class [8][12]. No head-to-head RCT has been conducted; all comparisons are indirect.

Structural and Mechanistic Differences:

| Feature | Plecanatide (Trulance) | Linaclotide (Linzess) | |---------|----------------------|---------------------| | Parent molecule | Human uroguanylin | Bacterial STa enterotoxin | | Amino acids | 16 | 14 | | Disulfide bonds | 2 (Cys4-Cys12, Cys7-Cys15) | 3 (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13) | | pH-dependent activation | Yes (maximal at pH 5.0) | No (pH-independent) | | Active metabolite | des-Tyr16-plecanatide | des-Tyr14-linaclotide (MM-419447) | | Food effect | None (take with or without food) | Yes (take on empty stomach) | | Available doses | 3 mg | 72, 145, 290 mcg |

Efficacy Comparison (Indirect, from Respective Phase III Programs):

| Endpoint | Plecanatide 3 mg | Linaclotide 290 mcg (IBS-C) | |----------|-----------------|---------------------------| | FDA composite IBS-C responder | 24-30% vs 14-18% PBO | 34% vs 17% PBO | | Abdominal pain responder (IBS-C) | 21-22% vs 14-15% PBO | 35-49% vs 27-34% PBO | | NNT for IBS-C | ~6-8 | ~5-6 | | CIC CSBM overall responder | 20-21% vs 10-13% PBO | 21-22% vs 6-9% PBO |

In the Shah et al. (2018) network meta-analysis, linaclotide 290 mcg ranked highest for overall IBS-C efficacy, while plecanatide 3 mg showed comparable but numerically lower effect sizes [8]. For CIC, efficacy differences were smaller.

Tolerability Comparison (The Key Differentiator):

| Safety Endpoint | Plecanatide 3 mg | Linaclotide 290 mcg | |-----------------|-----------------|---------------------| | Diarrhea rate (all trials) | 4.3-5.9% | 14-20% | | Severe diarrhea | less than 1% | 2-5% | | Diarrhea-related discontinuation | ~1% | 4-5% | | Any adverse event leading to discontinuation | 2-3% | 6-8% |

The approximately 3-4 fold lower diarrhea rate is plecanatide's primary clinical advantage and the main reason clinicians select it over linaclotide for diarrhea-sensitive patients [8].

6.2 Plecanatide vs Lubiprostone

Lubiprostone (Amitiza), a chloride channel type 2 (ClC-2) activator, was the first prosecretory agent approved for CIC (2006) and IBS-C (2008) [14][15]:

| Feature | Plecanatide | Lubiprostone | |---------|------------|-------------| | Mechanism | GC-C agonist (cGMP pathway) | ClC-2 activator (direct chloride secretion) | | Dosing | 3 mg QD | 24 mcg BID (CIC) or 8 mcg BID (IBS-C) | | Food requirement | None | Take with food (reduces nausea) | | Nausea rate | less than 2% | 29-31% (CIC dose) | | Diarrhea rate | 4-6% | 12-13% | | Abdominal pain improvement | Yes (IBS-C) | Modest | | Pregnancy category | Not studied (contraindicated under 6) | Category C |

Plecanatide offers meaningful advantages over lubiprostone: once-daily dosing (vs BID), no food requirement, dramatically lower nausea rates, and superior abdominal pain relief in IBS-C [14][15].

6.3 Positioning in CIC/IBS-C Treatment

Current ACG guidelines (2014, updated practice) position prosecretory agents after failure of lifestyle modifications and over-the-counter laxatives [20]. Within the prescription options:

First-line prosecretory agent considerations:

• Linaclotide when maximal efficacy is prioritized (more robust pain relief in IBS-C)
• Plecanatide when tolerability is prioritized (lower diarrhea, flexible dosing with food)
• Lubiprostone as an alternative when GC-C agonists are contraindicated or not tolerated

Clinical scenarios favoring plecanatide:

• Patients who discontinued linaclotide due to diarrhea
• Patients who prefer to take medication with meals
• Patients with mild IBS-C where moderate efficacy is acceptable
• Elderly patients where minimizing diarrhea-related dehydration risk is important

7. Dosing

The approved dose of plecanatide is 3 mg orally once daily for both CIC and IBS-C in adults [9]. Tablets should be swallowed whole. For patients unable to swallow tablets, the tablet may be crushed and mixed with applesauce or administered in water via a nasogastric or gastric feeding tube [9].

8. Safety and Side Effects

8.1 Diarrhea

Diarrhea is the most common adverse event, occurring in 4.3-5.9% of patients (vs 1.3-1.4% placebo) [1][2][3][9]. Most cases are mild to moderate and self-limiting. Severe diarrhea is rare (less than 1%). The low diarrhea rate is considered a distinguishing advantage of plecanatide over linaclotide [8].

8.2 Contraindications

Plecanatide carries the same pediatric contraindication as linaclotide: it is contraindicated in patients younger than 2 years of age due to the risk of serious dehydration [9]. This is based on the same class-effect neonatal mouse toxicology data showing fatal dehydration from GC-C agonist exposure in immature intestines. A boxed warning advises avoidance in children under 6 years of age [9]. Mechanical GI obstruction is also a contraindication [9].

8.3 Long-Term Safety

No systemic safety concerns have emerged because plecanatide is not absorbed systemically. No drug-drug interactions are expected, and no dose adjustments are required for hepatic or renal impairment [9].

9. Enhanced Safety Considerations

9.1 Pediatric Safety: The Boxed Warning in Context

The boxed warning for plecanatide (and linaclotide) regarding pediatric use requires careful clinical understanding [9]:

Contraindicated (under 2 years). In neonatal mouse models, GC-C agonists caused fatal secretory diarrhea and dehydration in mice aged 1-14 days, corresponding to intestinal developmental stages before GC-C expression reaches mature regulation. This is due to disproportionate GC-C receptor density and immature counter-regulatory mechanisms in the neonatal intestine [9].

Avoid use (under 6 years). Safety has not been established. The pediatric GI tract matures substantially between ages 2 and 6, but the lack of clinical data precludes establishing a safe dose. The recommendation to avoid use is precautionary [9].

Adolescents (6-17 years). Not FDA-approved for this age group, but the safety risk is expected to be low given mature intestinal physiology. No clinical trial data are available. Off-label use should be guided by pediatric gastroenterology consultation [9].

9.2 Diarrhea Management Protocol

While diarrhea rates are low with plecanatide, a structured management approach prevents unnecessary discontinuation [1][3][9]:

Grade 1 (mild, less than 4 stools/day above baseline). Continue plecanatide; ensure adequate hydration (at least 2 L/day oral fluids); reassure patient that mild diarrhea often resolves within the first 1-2 weeks of therapy.

Grade 2 (moderate, 4-6 stools/day above baseline). Consider temporary dose interruption for 2-3 days; resume when diarrhea resolves. If recurrent, consider alternating-day dosing (off-label, limited data).

Grade 3 (severe, more than 6 stools/day above baseline or hemodynamic compromise). Discontinue plecanatide. Evaluate for other etiologies (infection, IBD). Monitor electrolytes and renal function. Severe diarrhea with plecanatide is extremely rare (less than 1%).

Special populations at higher diarrhea risk:

• Elderly patients (less physiologic reserve for fluid losses)
• Patients on diuretics (compounded electrolyte depletion risk)
• Patients with pre-existing diarrhea-predominant symptoms (misdiagnosis -- consider IBS-D)

9.3 Electrolyte and Hydration Monitoring

Although systemic electrolyte disturbances have not been reported in plecanatide clinical trials (consistent with the low diarrhea rate and local mechanism), clinical vigilance is appropriate in specific populations [9]:

Patients on concurrent diuretics. The combination of a prosecretory agent and diuretic therapy may theoretically compound fluid and electrolyte losses. Baseline and periodic electrolyte panels (sodium, potassium, chloride, bicarbonate, magnesium) are recommended in patients on loop or thiazide diuretics [9].

Elderly patients. Age-related reductions in renal concentrating ability and thirst perception increase vulnerability to dehydration from any GI fluid losses. Lower threshold for monitoring and hydration counseling [9].

Patients with chronic kidney disease. Although no dose adjustment is needed (the drug is not renally cleared), these patients have less renal reserve to compensate for GI fluid losses. Monitor creatinine if diarrhea develops.

9.4 GI Obstruction Screening

Mechanical gastrointestinal obstruction is a contraindication because prosecretory agents can worsen distension and perforation risk in obstructed bowel [9]:

• Evaluate for red-flag symptoms before prescribing: new-onset constipation in patients over 50, unintentional weight loss, rectal bleeding, family history of colorectal cancer, iron deficiency anemia
• Age-appropriate colorectal cancer screening should be current before initiating chronic prosecretory therapy
• Discontinue immediately and evaluate if a patient on plecanatide develops signs of obstruction (abdominal distension, bilious vomiting, absent flatus, peritoneal signs)

9.5 Monitoring Recommendations

| Parameter | Frequency | Notes | |-----------|-----------|-------| | Symptom assessment (stool frequency, consistency, pain) | 4-6 weeks after initiation, then PRN | Evaluate response; consider alternative if no improvement by 6 weeks | | Blood tests | Not routinely required | No systemic absorption = no systemic monitoring needed | | Electrolytes | Only if diarrhea develops or in at-risk patients | Diuretic use, elderly, CKD | | Colorectal cancer screening | Per guidelines (before starting if overdue) | Rule out organic pathology | | Medication review | At initiation | Identify constipation-causing medications (opioids, anticholinergics, calcium channel blockers) that may require adjustment |

9.6 Pregnancy and Lactation

Pregnancy. No adequate human studies. Animal reproduction studies showed no evidence of fetal harm at doses up to 80-fold the human dose, but the drug is minimally absorbed, making systemic fetal exposure extremely unlikely. The prescribing information does not assign a pregnancy category under the PLLR system but does not contraindicate use [9].

Lactation. Given negligible systemic absorption (less than 0.1%), transfer into breast milk is expected to be negligible to nil. Furthermore, any trace amounts would be degraded in the infant's GI tract by the same proteolytic mechanisms that limit oral bioavailability. Risk to breastfed infants is considered very low, but formal studies are lacking [9].

10. Regulatory Status

United States (FDA): Trulance was approved for CIC in adults in January 2017 and for IBS-C in adults in January 2018 [9]. Synergy Pharmaceuticals, the original developer, declared bankruptcy in 2018, and the commercial rights were acquired by Bausch Health through its Salix Pharmaceuticals subsidiary.

Other Markets: Plecanatide has not been submitted for approval by the EMA or other major regulatory authorities outside the United States.

11. Related Peptides

See also: Linaclotide (Linzess/Constella), Semaglutide

• Linaclotide (Linzess/Constella) -- The first-in-class GC-C agonist, structurally modeled on bacterial STa with three disulfide bonds. More efficacious overall in IBS-C but with higher diarrhea rates.

12. References

1. [1] Miner PB Jr, Koltun WD, Wiener GJ, et al. (2017). A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients with Chronic Idiopathic Constipation. Am J Gastroenterol. DOI PubMed
2. [2] DeMicco M, Barrow L, Gao X, et al. (2017). Randomized Clinical Trial -- Efficacy and Safety of Plecanatide in the Treatment of Chronic Idiopathic Constipation. Therap Adv Gastroenterol. DOI PubMed
3. [3] Brenner DM, Fogel R, Dorn SD, et al. (2018). Efficacy, Safety, and Tolerability of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation -- Results of Two Phase 3 Randomized Clinical Trials. Am J Gastroenterol. DOI PubMed
4. [4] Miner PB Jr, Barrow L, Gao X, et al. (2019). Plecanatide for Irritable Bowel Syndrome with Constipation -- Phase III Efficacy and Safety. Am J Gastroenterol. DOI PubMed
5. [5] Shailubhai K, Comiskey S, Foss JA, et al. (2013). Plecanatide, an Oral Guanylate Cyclase C Agonist Acting Locally in the Gastrointestinal Tract, Is Safe and Well-Tolerated in Single Doses. Dig Dis Sci. DOI PubMed
6. [6] Shailubhai K, Palejwala V, Arjunan KP, et al. (2015). Plecanatide and Dolcanatide, Novel Guanylate Cyclase-C Agonists, Ameliorate Gastrointestinal Inflammation in Murine Models of Mucosal Inflammation. World J Gastrointest Pharmacol Ther. DOI PubMed
7. [7] Shailubhai K, Comiskey S, Foss JA, et al. (2015). Plecanatide, a Guanylate Cyclase C Receptor Agonist That Acts Locally in the GI Tract Has pH-Dependent Activity Mimicking Uroguanylin. Gastroenterology. DOI PubMed
8. [8] Shah ED, Kim HM, Schoenfeld P. (2018). Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation -- A Systematic Review and Meta-Analysis. Am J Gastroenterol. DOI PubMed
9. [9] TRULANCE Prescribing Information (2024). TRULANCE (Plecanatide) Tablets for Oral Use: Full Prescribing Information. Salix Pharmaceuticals / FDA. PubMed
10. [10] Hamra FK, Forte LR, Eber SL, et al. (1993). Uroguanylin -- Structure and Activity of a Second Endogenous Peptide That Stimulates Intestinal Guanylate Cyclase. Proc Natl Acad Sci USA. DOI PubMed
11. [11] Currie MG, Fok KF, Kato J, et al. (1992). Guanylin -- An Endogenous Activator of Intestinal Guanylate Cyclase. Proc Natl Acad Sci USA. DOI PubMed
12. [12] Waldman SA, Camilleri M. (2018). Guanylate Cyclase-C as a Therapeutic Target in Gastrointestinal Disorders. Gut. DOI PubMed
13. [13] Hannig G, Tchernychev B, Engel P, et al. (2022). Guanylate Cyclase-C Agonists as Peripherally Acting Treatments of Chronic Visceral Pain. Trends Pharmacol Sci. DOI PubMed
14. [14] Thomas RH, Luthin DR. (2015). Current and Emerging Treatments for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation -- Focus on Prosecretory Agents. Pharmacotherapy. DOI PubMed
15. [15] Barish CF, Drossman DA, Johanson JF, Ueno R. (2010). Efficacy and Safety of Lubiprostone in Patients with Chronic Constipation. Dig Dis Sci. DOI PubMed
16. [16] Chey WD, Lembo AJ, Lavins BJ, et al. (2012). Linaclotide for Irritable Bowel Syndrome with Constipation -- A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Gastroenterol. DOI PubMed
17. [17] Corsetti M, Tack J. (2013). Linaclotide -- A New Drug for the Treatment of Chronic Constipation and Irritable Bowel Syndrome with Constipation. United European Gastroenterol J. DOI PubMed
18. [18] Layer P, Stanghellini V, Chey WD, et al. (2014). Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults. Drugs. DOI PubMed
19. [19] Lacy BE, Mearin F, Chang L, et al. (2016). Bowel Disorders. Gastroenterology. DOI PubMed
20. [20] Ford AC, Moayyedi P, Lacy BE, et al. (2014). American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. Am J Gastroenterol. DOI PubMed